FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

CardioComm Solutions, Inc.
259 Yorkland Road, Suite 200
North York, ON M2J 0B5

2. Date of Material Change

July 24, 2014

3. News Release

The news release announcing the material change was disseminated on July 24, 2014, through Transmedia Industries. The news release was also filed with the British Columbia, Alberta and Ontario Securities Commissions on SEDAR.

4. Summary of Material Change

CardioComm Solutions, Inc. (the "Company") announced that it has closed the first tranche of its previously announced private placement equity financing. Under the financing, the Company issued 3,300,000 units at a price of $0.05 per unit, for gross proceeds of $165,000. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.07.

5.1 Full Description of Material Change

See attached news release.

5.2 Disclosure for Restructuring Transactions

N/A

6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been intentionally omitted from this material change report.

8. Executive Officer

Etienne Grima, CEO, 1-877-977-9425

9. Date of Report

July 24, 2014

FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

July 24, 2014

CardioComm Solutions Closes Equity Financing

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm Solutions" or the "Company") announced today it had closed the first tranche of its previously announced private placement equity financing. Under the closing of the first tranche, the Company issued 3,300,000 units at a price of $0.05 per unit, for gross proceeds of $165,000. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.07. For further information regarding the financing, please see the Company's press release that was issued on July 11, 2014. The gross proceeds from the financing will be used towards the development of next generation wireless ECG device products and expanded promotion of the GEMS™ WIN launch. The shares and warrants issued by the Company are subject to a four month hold period which expires on November 25, 2014. The Company also confirmed that it will continue its current private placement equity financing offer.

About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on

circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.